WO2019156568A8 - Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy - Google Patents
Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy Download PDFInfo
- Publication number
- WO2019156568A8 WO2019156568A8 PCT/NL2019/050092 NL2019050092W WO2019156568A8 WO 2019156568 A8 WO2019156568 A8 WO 2019156568A8 NL 2019050092 W NL2019050092 W NL 2019050092W WO 2019156568 A8 WO2019156568 A8 WO 2019156568A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- immune checkpoint
- cancer
- methods
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the field of biomarker development for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds. Provided are assays for quantifying PD-1 expression (i.e. immunostaining intensity) in cells present in a tumor sample (i.e. intratumoral cells), which are advantageously used to identify a unique sub-population of intratumoral cells referred to herein as PD-1 T cells, which serves as a biomarker for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab). The present invention also provides methods of selecting a human subject diagnosed with cancer (e.g. non-small cell lung cancer (NSCLC)) suitable for immune checkpoint therapy with agents such as PD-1 inhibitors (e.g. nivolumab) and/or PD-L1 inhibitors (e.g. atezolizumab) alone or in combination with other therapeutic agents (e.g. CTLA- 4 inhibitor compound, e.g. ipilimumab), methods for predicting responsiveness to immune checkpoint therapy with agents such as PD-1 inhibitors and/or PD-L1 inhibitors, and method of treatment of a human subject diagnosed with cancer using PD-1 inhibitors and/or PD-L1 inhibitors alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2020422A NL2020422B1 (en) | 2018-02-12 | 2018-02-12 | Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy. |
| NL2020422 | 2018-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2019156568A1 WO2019156568A1 (en) | 2019-08-15 |
| WO2019156568A8 true WO2019156568A8 (en) | 2019-10-03 |
Family
ID=62002361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NL2019/050092 WO2019156568A1 (en) | 2018-02-12 | 2019-02-12 | Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy |
Country Status (2)
| Country | Link |
|---|---|
| NL (1) | NL2020422B1 (en) |
| WO (1) | WO2019156568A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210252143A1 (en) * | 2018-06-22 | 2021-08-19 | Merck Patent Gmbh | Methods of treating cancer using combination therapy |
| AU2019375416A1 (en) | 2018-11-05 | 2021-05-27 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive T-cells |
| EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2022017435A1 (en) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | SERIES OF BIOMARKERS OF CONSENSUS SEQUENCES IN CDR3 SEQUENCE OF TCR-β CHAIN AND APPLICATION THEREOF |
| TW202242085A (en) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | Devices and processes for automated production of tumor infiltrating lymphocytes |
| EP4301138A2 (en) | 2021-03-05 | 2024-01-10 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| CN113125751B (en) * | 2021-04-12 | 2022-11-08 | 首都医科大学附属北京世纪坛医院 | Method for predicting PD-L1 level in breast cancer tumor tissue by peripheral blood PD-1/PD-L1 |
| JP2024519029A (en) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | PD-1 gene-edited tumor-infiltrating lymphocytes and their use in immunotherapy |
| CN113933505B (en) * | 2021-12-15 | 2022-04-05 | 北京市肿瘤防治研究所 | A set of multidimensional analysis to predict the efficacy of gastric cancer immunotherapy TIIC index and its application |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| WO2024033381A1 (en) * | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| CN115869406B (en) * | 2022-11-10 | 2024-10-15 | 杭州师范大学 | Use of PD-1 antibody combined with UFSP2 covalent inhibitor in the preparation of drugs for treating tumors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
| RU2406760C3 (en) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching |
| KR101607288B1 (en) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| CN104945508B (en) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | For the antibody of people's programmed death receptor PD-1 |
-
2018
- 2018-02-12 NL NL2020422A patent/NL2020422B1/en not_active IP Right Cessation
-
2019
- 2019-02-12 WO PCT/NL2019/050092 patent/WO2019156568A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019156568A1 (en) | 2019-08-15 |
| NL2020422B1 (en) | 2019-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019156568A8 (en) | Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX2023010805A (en) | Therapeutic and diagnostic methods for cancer. | |
| Quagliariello et al. | Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab | |
| AU2007255110A8 (en) | Circulating tumor cell assay | |
| Holdenrieder et al. | Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer | |
| WO2016196298A8 (en) | Therapeutic and diagnostic methods for cancer | |
| US20180140578A1 (en) | Methods and compositions for the diagnosis and selective treatment of cancer | |
| WO2013009655A3 (en) | Uses of labeled hsp90 inhibitors | |
| BR112015023120A2 (en) | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual | |
| WO2018187496A8 (en) | Plasma based protein profiling for early stage lung cancer prognosis | |
| WO2009067546A3 (en) | Lung cancer markers and uses thereof | |
| US8765713B2 (en) | Method for determination of sensitivity to anti-cancer agent | |
| KR20100130587A (en) | Anti-cancer drug susceptibility determination method | |
| EP4461825A3 (en) | Tumor-infiltrating t-cells for use in the treatment of cancer | |
| PH12020552011A1 (en) | Biomarkers for determining the effectiveness of immune checkpoint inhibitors | |
| WO2017217807A3 (en) | Biomarker comprising nckap1 as effective ingredient for diagnosing colorectal cancer or for predicting metastasis and prognosis of colorectal cancer | |
| Sanmamed et al. | Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients | |
| Guidetti et al. | Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma | |
| MX339340B (en) | Methods for predicting and improving the survival of gastric cancer patients. | |
| US11603568B2 (en) | NOX2 as a biomarker of radiotherapy efficiency in cancer patients | |
| WO2011103330A3 (en) | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury | |
| Kremer et al. | Nucleosomes in pancreatic cancer patients during radiochemotherapy | |
| ATE483979T1 (en) | GENE ANLN RELATED TO NON-SMALL CELL LUNG CANCER AND ITS INTERACTIONS WITH RHOA | |
| Luke et al. | Phase 1/2 study of the indoleamine 2, 3-dioxygenase 1 inhibitor linrodostat mesylate combined with nivolumab or nivolumab and ipilimumab in advanced solid tumors or hematologic malignancies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19714882 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19714882 Country of ref document: EP Kind code of ref document: A1 |